- Vous n`avez pas encore de produits dans votre panier.
Déclaration sur les mutations virales
The Statement on Detection of Mutant Viruses
Date: 30 Agust, 2024
Product: Green Spring® SARS-CoV-2 Antigen Rapid Test Kit (Colloidal Gold)
We, Shenzhen Lvshiyuan Biotechnology Co., Ltd., as the manufacturer, hereby declare that Green Springs SARS-CoV-2 Antigen Rapid Test Kit (Colloidal Gold) can detect the following SARS-CoV-2 Virus variants which is listed as 'variants of concern (VOC)'& 'variants of interest (VOI) & Variants under monitoring (VUMs)'by the World Health Organization. VOC refers to the large number and wide range of cases caused worldwide, and data confirms its transmission ability, strong toxicity, or reduced effectiveness of vaccines and clinical treatments. VOI refers to a confirmed case of community transmission, or has been found in multiple countries, but has not yet formed a large-scale infection. VUM refers to a SARS-CoV-2 variant with genetic changes that are suspected to affect virus characteristics with some indication that it may pose a future risk, but evidence of phenotypic or epidemiological impact is currently unclear, requiring enhanced monitoring and repeat assessment pending new evidence.
The new coronavirus (SARS-CoV-2 or 2019-nCoV) is a non-segmented forward RNA virus.
This is the cause of the new type of coronavirus pneumonia (COVID-19), which is highly contagious in humans. The SARS-CoV-2 virus has several structural proteins, including spikes (S), envelope (E), membrane (M) and nucleocapsid (N).
The SARS-CoV-2 virus has the characteristics of strong nucleocapsid (N) protein stability.
The mutant virus strains that have been found worldwide are derived from the SARS-CoV-2 20B/GR evolutionary strain (lineage B.1.1.7), including many mutation, the mutation location is the spike (S) protein of the new coronavirus, which is the location where the SARS-CoV-2 virus uses to bind to the cell's ACE2 receptor.
The SARS-CoV-2 Antigen Rapid Test Kit produced by Shenzhen Lvshiyuan Biotechnology Co., Ltd. is used for in vitro qualitative detection of SARS-CoV-2 virus nucleocapsid (N) protein in human nasopharyngeal , oropharyngeal , anterior -nasal or saliva samples.
It can be seen that the mutation sites of mutated virus strains including XBB.1.5 strain have no effect on the detection rate of the kits produced by our company. The kit is suitable for assay of the SARS-CoV-2 variant virus as listed in the table above.
Product: Green Spring® SARS-CoV-2 Antigen Rapid Test Kit (Colloidal Gold)
We, Shenzhen Lvshiyuan Biotechnology Co., Ltd., as the manufacturer, hereby declare that Green Springs SARS-CoV-2 Antigen Rapid Test Kit (Colloidal Gold) can detect the following SARS-CoV-2 Virus variants which is listed as 'variants of concern (VOC)'& 'variants of interest (VOI) & Variants under monitoring (VUMs)'by the World Health Organization. VOC refers to the large number and wide range of cases caused worldwide, and data confirms its transmission ability, strong toxicity, or reduced effectiveness of vaccines and clinical treatments. VOI refers to a confirmed case of community transmission, or has been found in multiple countries, but has not yet formed a large-scale infection. VUM refers to a SARS-CoV-2 variant with genetic changes that are suspected to affect virus characteristics with some indication that it may pose a future risk, but evidence of phenotypic or epidemiological impact is currently unclear, requiring enhanced monitoring and repeat assessment pending new evidence.
WHO Categories | WHO Label | Pango Lineage | Date of Designation |
---|---|---|---|
Variants Of Concern (VOC) | Alpha | B.1.1.7 | Sep 20 |
Beta | B.1.351 | Mai 20 | |
Gamma | P.1 | Nov 20 | |
Delta | B.1.617.2 | Okt 20 | |
Omicron | B.1.1.529 | Nov 21 | |
Variants Of Interest (VOI) | Epsilon | B.1.427 | Feb 21 |
B.1.429 | Jun 21 | ||
Eta | B.1.525 | Feb 21 | |
Iota | B.1.526 | Feb 21 | |
Kappa | B.1.617.1 | Mai 21 | |
N/A | B.1.617.3 | Mai 21 | |
Zeta | P.2 | Feb 21 | |
Mu | B.1.621, B.1.621.1 | Sep 21 | |
IHU | B.1.640.2 | Sep 21 | |
Variants under monitoring (VUMs) | BA.1 xAY.4 recombinant | Mrz 22 | |
B.1.640 | Nov 21 | ||
BA.1 | Nov 21 | ||
BA.2 | Feb 22 | ||
BA.2.12.1 | Feb 22 | ||
BA.3 | Feb 22 | ||
BA.4 | Jan 22 | ||
BA.5 | Jan 22 | ||
BF.7 | Mrz 22 | ||
BA.2.75 | Mai 22 | ||
BQ.1.1 | Aug 22 | ||
XBB | Sep 22 | ||
BQ.1 | Sep 22 | ||
Pirola(BA.2.86) | Aug 23 | ||
JN.1 | Aug 23 | ||
KP.2 | Feb 24 |
The new coronavirus (SARS-CoV-2 or 2019-nCoV) is a non-segmented forward RNA virus.
This is the cause of the new type of coronavirus pneumonia (COVID-19), which is highly contagious in humans. The SARS-CoV-2 virus has several structural proteins, including spikes (S), envelope (E), membrane (M) and nucleocapsid (N).
The SARS-CoV-2 virus has the characteristics of strong nucleocapsid (N) protein stability.
The mutant virus strains that have been found worldwide are derived from the SARS-CoV-2 20B/GR evolutionary strain (lineage B.1.1.7), including many mutation, the mutation location is the spike (S) protein of the new coronavirus, which is the location where the SARS-CoV-2 virus uses to bind to the cell's ACE2 receptor.
The SARS-CoV-2 Antigen Rapid Test Kit produced by Shenzhen Lvshiyuan Biotechnology Co., Ltd. is used for in vitro qualitative detection of SARS-CoV-2 virus nucleocapsid (N) protein in human nasopharyngeal , oropharyngeal , anterior -nasal or saliva samples.
It can be seen that the mutation sites of mutated virus strains including XBB.1.5 strain have no effect on the detection rate of the kits produced by our company. The kit is suitable for assay of the SARS-CoV-2 variant virus as listed in the table above.